Use of Botulinum Toxin in Urologic Diseases

被引：10
作者：
Chermansky, Christopher J.
Chancellor, Michael B.
机构：
[1] Univ Pittsburgh, Sch Med, Dept Urol, Pittsburgh, PA USA
[2] Beaumont Hlth, Dept Urol, Royal Oak, MI USA
[3] Oakland Univ, William Beaumont Sch Med, Royal Oak, MI USA
来源：
UROLOGY | 2016年 / 91卷
关键词：
DETRUSOR-SPHINCTER DYSSYNERGIA; IDIOPATHIC OVERACTIVE BLADDER; LIPOSOME-ENCAPSULATED ONABOTULINUMTOXINA; QUALITY-OF-LIFE; URINARY-INCONTINENCE; DOUBLE-BLIND; A TOXIN; EFFICACY; IMPROVES; SYMPTOMS;
D O I：
10.1016/j.urology.2015.12.049
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
OnabotulinumtoxinA (onaBoNTA) is approved by the US Food and Drug Administration for the treatment of urinary incontinence due to neurogenic detrusor overactivity and for the treatment of refractory overactive bladder. As a treatment for benign prostatic hyperplasia, onaBoNTA showed no difference over placebo in recently published studies. In contrast, treating interstitial cystitis/bladder pain syndrome with onaBoNTA has shown efficacy, and the current American Urological Association guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome lists onaBoNTA as fourth-line treatment. This comprehensive review will present all studied applications of onaBoNTA within the lower urinary tract. (C) 2016 Elsevier Inc.
引用
收藏
页码：21 / 32
页数：12
相关论文
共 39 条
[1]   Botulinum toxin type A for chronic pain and pelvic floor spasm in women - A randomized controlled trial [J].
Abbott, Jason A. ;
Jarvis, Sherin K. ;
Lyons, Stephen D. ;
Thomson, Angus ;
Vancaille, Thierry G. .
OBSTETRICS AND GYNECOLOGY, 2006, 108 (04) :915-923
[2]  
Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
[3]   Botulinum Toxin Type A (BOTOX) for Refractory Myofascial Pelvic Pain [J].
Adelowo, Amos ;
Hacker, Michele R. ;
Shapiro, Alex ;
Modest, Anna Merport ;
Elkadry, Eman .
FEMALE PELVIC MEDICINE AND RECONSTRUCTIVE SURGERY, 2013, 19 (05) :288-292
[4]   Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity [J].
Apostolidis, A ;
Dasgupta, P ;
Fowler, CJ .
EUROPEAN UROLOGY, 2006, 49 (04) :644-650
[5]   Comparison of neuromuscular blockade and recovery with botulinum toxins A and F [J].
Billante, CR ;
Zealear, DL ;
Billante, M ;
Reyes, JH ;
Sant'Anna, G ;
Rodriguez, R ;
Stone, RE .
MUSCLE & NERVE, 2002, 26 (03) :395-403
[6]   Drug Insight: biological effects of botulinum toxin A in the lower urinary tract [J].
Chancellor, Michael B. ;
Fowler, Clare J. ;
Apostolidis, Apostolos ;
de Groat, William C. ;
Smith, Christopher P. ;
Somogyi, George T. ;
Aoki, K. Roger .
NATURE CLINICAL PRACTICE UROLOGY, 2008, 5 (06) :319-328
[7]   Pharmacotherapy for neurogenic detrusor overactivity [J].
Chancellor, Michael B. ;
Anderson, Rodney U. ;
Boone, Timothy B. .
AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION, 2006, 85 (06) :536-545
[8]   OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity [J].
Chancellor, Michael B. ;
Patel, Vaishali ;
Leng, Wendy W. ;
Shenot, Patrick J. ;
Lam, Wayne ;
Globe, Denise R. ;
Loeb, Alex L. ;
Chapple, Christopher R. .
NEUROLOGY, 2013, 81 (09) :841-848
[9]   OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial [J].
Chapple, Christopher ;
Sievert, Karl-Dietrich ;
MacDiarmid, Scott ;
Khullar, Vik ;
Radziszewski, Piotr ;
Nardo, Christopher ;
Thompson, Catherine ;
Zhou, Jihao ;
Haag-Molkenteller, Cornelia .
EUROPEAN UROLOGY, 2013, 64 (02) :249-256
[10]   The effects of antimuscarinic treatments in overactive bladder: An update of a systematic review and meta-analysis [J].
Chapple, Christopher R. ;
Khullar, Vik ;
Gabriel, Zahava ;
Muston, Dominic ;
Bitoun, Caty Ebel ;
Weinstein, David .
EUROPEAN UROLOGY, 2008, 54 (03) :543-562
1234